Clinical (A) and Molecular (B) Characteristics of AML Patients With MLL Cleavage
| A. Patient Characteristics . | |||||
|---|---|---|---|---|---|
| . | . | . | |||
| Patient No. . | Age/Sex . | FAB . | WBC . | % Age Blasts . | Cytogenetics . |
| 593 | 35/M | M5 | 104 | 96 | 46,XY [25] |
| 722 | 38/M | M4 | 160 | 80 | 46,XY[1]/47,XY, +8 [39] |
| 975 | 55/M | M4 | 23.5 | 42 | 46,XY [20] |
| B. Southern Blot Hybridization With the B859 cDNA and 19 Genomic Probes | |||||
| A. Patient Characteristics . | |||||
|---|---|---|---|---|---|
| . | . | . | |||
| Patient No. . | Age/Sex . | FAB . | WBC . | % Age Blasts . | Cytogenetics . |
| 593 | 35/M | M5 | 104 | 96 | 46,XY [25] |
| 722 | 38/M | M4 | 160 | 80 | 46,XY[1]/47,XY, +8 [39] |
| 975 | 55/M | M4 | 23.5 | 42 | 46,XY [20] |
| B. Southern Blot Hybridization With the B859 cDNA and 19 Genomic Probes | |||||
| Restriction Enzyme | Germline Fragments (kb) | Fragments Induced by Topo II Inhibitor (kb)* |
| BamHI | 8.3 | 6.7, 1.5 |
| HindIII | 15 | 12.5, 2.5 |
| BgI III | 3.1, 6 | 3.1, 4.6, 1.4 |
| EcoRI | 4.6, 5, 4 | 4.6, 5, (0.7), 3.3 |
| Restriction Enzyme | Germline Fragments (kb) | Fragments Induced by Topo II Inhibitor (kb)* |
| BamHI | 8.3 | 6.7, 1.5 |
| HindIII | 15 | 12.5, 2.5 |
| BgI III | 3.1, 6 | 3.1, 4.6, 1.4 |
| EcoRI | 4.6, 5, 4 | 4.6, 5, (0.7), 3.3 |
The 3′ fragment identified by the 19 genomic probe is underlined. The 0.7-kb fragment in EcoRI digests is unlikely to be detected with a cDNA probe in view of its size and limited exon content.